<DOC>
	<DOCNO>NCT00989079</DOCNO>
	<brief_summary>Ertugliflozin ( PF-04971729 , MK-8835 ) new compound propose treatment Type 2 diabetes mellitus . The primary purpose study evaluate safety tolerability along pharmacokinetics single escalate dos ertugliflozin feed fasted condition healthy volunteer .</brief_summary>
	<brief_title>A Single Escalating Dose Study Of Ertugliflozin ( PF-04971729 , MK-8835 ) Under Fed Fasted Conditons In Healthy Volunteers ( MK-8835-036 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy male and/or female subject non childbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Single Ascending Dose Study healthy subject</keyword>
</DOC>